Michael Barbella, Managing Editor10.10.23
Australia's Patent Office has granted a patent to the University of Iowa Research Foundation (UIRF) for cardiovascular disease detection technology.
The patent was exclusively licensed to Cardio Diagnostics Holdings Inc. from UIRF. It was co-invented by Cardio Diagnostics Founders, Meesha Dogan, Ph.D., (CEO), and Robert Philibert, M.D., Ph.D., (chief medical officer). Patent Application No. 2017277666 is titled, “Compositions and Methods for Detecting Predisposition to Cardiovascular Disease.”
“Securing this Australian patent is a significant step forward in enhancing our intellectual property portfolio globally,” Dogan stated. “This solidifies our commitment to delivering vital cardiovascular screening, detecting, and monitoring solutions to patients in Australia and worldwide.”
This Australian patent complements its three other granted patents in the United States, Europe, and China, further strengthening Cardio Diagnostics’ intellectual property portfolio.
“We are dedicated to supporting pioneering research that can make a real difference to healthcare worldwide. Cardio Diagnostics exemplifies the groundbreaking innovations at the University of Iowa, and we are excited to see their AI-driven solutions prevent heart disease and save lives in Australia and globally,” UIRF Executive Director Marie Kerbeshian, Ph.D., added.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary artificial intelligence-driven Integrated Genetic-Epigenetic Engine (core technology) for cardiovascular disease to help improve cardiovascular disease prevention, detection, and treatment.
The University of Iowa Research Foundation is part of the University of Iowa Office of the Vice President for Research, which provides researchers and scholars with resources, guidance, and inspiration to secure funding, collaborate, innovate, and forge frontiers of discovery.
The patent was exclusively licensed to Cardio Diagnostics Holdings Inc. from UIRF. It was co-invented by Cardio Diagnostics Founders, Meesha Dogan, Ph.D., (CEO), and Robert Philibert, M.D., Ph.D., (chief medical officer). Patent Application No. 2017277666 is titled, “Compositions and Methods for Detecting Predisposition to Cardiovascular Disease.”
“Securing this Australian patent is a significant step forward in enhancing our intellectual property portfolio globally,” Dogan stated. “This solidifies our commitment to delivering vital cardiovascular screening, detecting, and monitoring solutions to patients in Australia and worldwide.”
This Australian patent complements its three other granted patents in the United States, Europe, and China, further strengthening Cardio Diagnostics’ intellectual property portfolio.
“We are dedicated to supporting pioneering research that can make a real difference to healthcare worldwide. Cardio Diagnostics exemplifies the groundbreaking innovations at the University of Iowa, and we are excited to see their AI-driven solutions prevent heart disease and save lives in Australia and globally,” UIRF Executive Director Marie Kerbeshian, Ph.D., added.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary artificial intelligence-driven Integrated Genetic-Epigenetic Engine (core technology) for cardiovascular disease to help improve cardiovascular disease prevention, detection, and treatment.
The University of Iowa Research Foundation is part of the University of Iowa Office of the Vice President for Research, which provides researchers and scholars with resources, guidance, and inspiration to secure funding, collaborate, innovate, and forge frontiers of discovery.